Clinical Trial Phases Explained: From First Dose to Pharmacy Shelf
There are four phases of clinical trials, but what actually happens inside each one? A new medicine passes through four gates before reaching patients:
- Phase 1 tests safety in 20 to 80 healthy volunteers
- Phase 2 asks whether the drug actually works in 100 to 500 patients
- Phase 3 provides definitive proof in thousands of patients across dozens of countries
- Phase 4 monitors safety in the real world for years after approval
The entire journey takes 10 to 15 years and costs over $1 billion per approved drug. Only about 12% of drugs that enter phase 1 ever make it to patients (FDA: The Drug Development Process).
Phase 1: first in human
After years of lab research and animal studies, the drug enters a human being for the very first time. Twenty to eighty healthy volunteers are carefully monitored in a hospital setting. The only question is safety, not whether the drug works. Approximately 70% of drugs pass phase 1.
Phase 1 uses a technique called dose escalation. It starts with SAD, single ascending dose, where small groups receive one low dose. If safe, the next group gets a higher dose. Then comes MAD, multiple ascending dose, testing repeated doses. The goal is to find the MTD, maximum tolerated dose: the highest dose with acceptable side effects. This sets the dose for phase 2.
Volunteers are under 24/7 medical monitoring with continuous ECG and frequent blood draws.
Phase 2: does it work?
Phase 2 is where the drug enters patient volunteers for the first time. One hundred to five hundred people who actually have the target condition receive the drug. The question shifts from "is it safe?" to "does it work?"
This is the bottleneck of drug development. Only about 33% of drugs pass phase 2. If 10 drugs enter, only three make it out.
Phase 2 is divided into two parts:
- Phase IIA is a small pilot study looking for a signal of efficacy. Does the biological mechanism hold up in humans?
- Phase IIB is a larger, randomized, double-blind study to find the optimal dose for phase 3.
The go-or-no-go decision after phase 2 is the most critical moment in drug development. A negative phase 2 usually kills the entire program.
Phase 3: the definitive test
Phase 3 enrolls 1,000 to 5,000 or more patients across dozens of hospitals and countries. The design is the gold standard: randomized, double-blind, and placebo-controlled. The new drug is compared directly to the current standard treatment.
This phase costs $20 to $100 million per trial. About 50 to 60% succeed. Phase 3 is designed with 90% statistical power, meaning the trial has a 90% chance of detecting the drug's effect if it truly exists.
- Randomization eliminates selection bias by randomly assigning patients to drug or placebo.
- Double-blinding prevents expectation bias: neither the patient nor the doctor knows who gets what.
Phase 3 takes 2 to 5 years, making it the longest and most expensive phase. If successful, the company files an NDA with the FDA.
Phase 4: the watch continues
Even after a drug is approved, the research continues. Phase 4 is post-marketing surveillance, monitoring thousands to millions of real-world patients over many years.
Phase 3 trials might miss a side effect that occurs in only 1 in 5,000 patients. Phase 4 catches it. The FDA adverse event reporting system, FAERS, is always watching (FDA: FDA Adverse Event Reporting System).
Phase 4 has led to some of the most famous drug withdrawals in history. Vioxx was approved for arthritis in 1999 but withdrawn in 2004 after a phase 4 study showed increased heart attack risk. An estimated 60,000 deaths were attributed to it. Fen-phen, a weight loss drug, was withdrawn in 1997 after reports of valvular heart disease.
These cases show why phase 4 never really ends.
The go/no-go gates
Between each phase there is a go-or-no-go gate:
- The data safety monitoring board reviews safety data at every phase. If toxicity is unacceptable, the drug stops immediately.
- The drug must meet its primary efficacy endpoint.
- The end-of-phase-2 meeting with the FDA is the most critical gate. They must agree on the phase 3 design before it starts.
- The sponsor must still see commercial viability.
The brutal funnel
Out of 5,000 to 10,000 initial compounds screened, about 5 enter human testing. Three pass phase 1. Only one or two make it through phase 2. About one reaches phase 3 and gets approved.
The total cost per approved drug, including all the failures that paid for it, is $1 to $2 billion. Each failure funds the knowledge that leads to the next success.
The complete timeline
- Phase 1: 3 to 9 months, 20 to 80 subjects
- Phase 2: 6 to 24 months, 100 to 500 patients
- Phase 3: 2 to 5 years, thousands of patients
- FDA review: 6 to 10 months
- Phase 4: surveillance for the entire life of the drug
Total journey: 10 to 15 years from discovery to your medicine cabinet.
The bottom line
Phase 1 asks: is it safe? Phase 2 asks: does it work? Phase 3 proves it beyond doubt in thousands of patients. And phase 4 keeps watching even after approval.
Every medicine you rely on passed through these four gates. The system is rigorous by design, because your safety depends on it.
This article is based on the Clarity Clinical Solutions video "Clinical Trial Phases." Watch it here: Clinical Trial Phases
References
- Clarity Clinical Solutions — "Clinical Trial Phases" (video, source of the phase descriptions and statistics). https://www.youtube.com/watch?v=Rsly8eFM-ps
- FDA — The Drug Development Process. https://www.fda.gov/drugs/development-approval-process-drugs
- FDA — FDA Adverse Event Reporting System (FAERS). https://www.fda.gov/drugs/surveillance/fda-adverse-event-reporting-system-faers